Cargando…

The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice

The Wnt/β-catenin pathway confers a chain of molecular events in livers affected by non-alcoholic steato-hepatitis (NASH). Namodenoson, a selective agonist of the A3 adenosine receptor (A3AR), which is highly expressed in pathological liver cells, induces a robust anti-inflammatory effect in the liv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fishman, Pnina, Cohen, Shira, Itzhak, Inbal, Amer, Johnny, Salhab, Ahmad, Barer, Faina, Safadi, Rifaat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844636/ https://www.ncbi.nlm.nih.gov/pubmed/31638172 http://dx.doi.org/10.3892/ijmm.2019.4364

Ejemplares similares

Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A(3) Adenosine Receptor Agonist Piclidenoson
por: Cohen, Shira, et al.
Publicado: (2018)

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
por: Safadi, Rifaat, et al.
Publicado: (2021)

Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways
por: Itzhak, Inbal, et al.
Publicado: (2023)

A(3) Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect: In Vivo Studies and Molecular Mechanism of Action
por: Cohen, Shira, et al.
Publicado: (2014)

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial
por: Stemmer, Salomon M., et al.
Publicado: (2021)

25(OH) D3 alleviate liver NK cytotoxicity in acute but not in chronic fibrosis model of BALB/c mice due to modulations in vitamin D receptor
por: Salhab, Ahmad, et al.
Publicado: (2020)

Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis
por: Salhab, Ahmad, et al.
Publicado: (2022)

Targeting the A(3) adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
por: Cohen, Shira, et al.
Publicado: (2019)

The Immune Interplay between Thyroid Papillary Carcinoma and Hepatic Fibrosis
por: Muhanna, Nidal, et al.
Publicado: (2015)

Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A(3 )adenosine receptor expression
por: Ochaion, Avivit, et al.
Publicado: (2006)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease
por: Amer, Johnny, et al.
Publicado: (2018)

Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data
por: Fishman, Pnina
Publicado: (2022)

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
por: Hartmann, Phillipp, et al.
Publicado: (2022)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Alleviation of Hepatic Steatosis by Alpha-Defensin Is Associated with Enhanced Lipolysis
por: Maraga, Emad, et al.
Publicado: (2023)

Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/−) mice
por: Yang, Jin, et al.
Publicado: (2017)

Structural Correlates of PPAR Agonist Rescue of Experimental Chronic Alcohol-Induced Steatohepatitis
por: Ramirez, Teresa, et al.
Publicado: (2012)

β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model
por: Zigmond, Ehud, et al.
Publicado: (2014)

Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2020)

GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress
por: Kim, Hyeon Ju, et al.
Publicado: (2020)

Putative role of the adenosine A(3) receptor in the antiproliferative action of N(6)-(2-isopentenyl)adenosine
por: Blad, Clara C., et al.
Publicado: (2011)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis
por: Yu, Amy, et al.
Publicado: (2022)

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
por: Xue, Huan, et al.
Publicado: (2023)

Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects
por: Fishman, Pnina, et al.
Publicado: (2023)

Natural Killer Cell-Dependent Anti-Fibrotic Pathway in Liver Injury via Toll-Like Receptor-9
por: Abu-Tair, Lina, et al.
Publicado: (2013)

Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer‐BioNTech COVID‐19 Vaccine in Medical Employees
por: Shafrir, Asher, et al.
Publicado: (2022)

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
por: Griffett, Kristine, et al.
Publicado: (2015)

Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan
por: Park, Jung Gyu, et al.
Publicado: (2019)

Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis
por: Cabrera, Daniel, et al.
Publicado: (2017)

The phytochemical polydatin ameliorates non‐alcoholic steatohepatitis by restoring lysosomal function and autophagic flux
por: Chen, Xiaoting, et al.
Publicado: (2019)

Glucosinolates Extracts from Brassica juncea Ameliorate HFD-Induced Non-Alcoholic Steatohepatitis
por: Sheu, Ming-Jen, et al.
Publicado: (2023)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non‐alcoholic steatohepatitis model
por: Shimizu, Yoshio, et al.
Publicado: (2020)

Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells
por: Yamauchi, Akihiro, et al.
Publicado: (2017)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

The PI3K–NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis
por: Fishman, Pnina, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_m3u557k2n7271ljsco6ukouqdc